Literature DB >> 10373716

Aspirin and ticlopidine after routine coronary stenting: the gold standard as of 1999.

P A McCullough1, K R Marks.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10373716     DOI: 10.1023/a:1008922925054

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  21 in total

1.  Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial.

Authors:  H Schühlen; M Hadamitzky; H Walter; K Ulm; A Schömig
Journal:  Circulation       Date:  1997-04-15       Impact factor: 29.690

2.  Intracoronary stenting and risk for major adverse cardiac events during the first month.

Authors:  H Schühlen; A Kastrati; J Dirschinger; J Hausleiter; S Elezi; A Wehinger; J Pache; M Hadamitzky; A Schömig
Journal:  Circulation       Date:  1998-07-14       Impact factor: 29.690

Review 3.  Coronary artery stents. American College of Cardiology.

Authors:  C J Pepine; D R Holmes
Journal:  J Am Coll Cardiol       Date:  1996-09       Impact factor: 24.094

4.  Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting.

Authors:  C M Goods; K F al-Shaibi; M W Liu; J S Yadav; A Mathur; S P Jain; L S Dean; S S Iyer; J M Parks; G S Roubin
Journal:  Am J Cardiol       Date:  1996-11-01       Impact factor: 2.778

5.  Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality.

Authors:  P A McCullough; R Wolyn; L L Rocher; R N Levin; W W O'Neill
Journal:  Am J Med       Date:  1997-11       Impact factor: 4.965

6.  The STIMS trial: the ticlopidine experience and its clinical applications. Swedish Ticlopidine Multicenter Study.

Authors:  L Janzon
Journal:  Vasc Med       Date:  1996       Impact factor: 3.239

7.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

8.  The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions.

Authors:  S R Steinhubl; M S Lauer; D P Mukherjee; D J Moliterno; A M Lincoff; S G Ellis; E J Topol
Journal:  J Am Coll Cardiol       Date:  1998-11       Impact factor: 24.094

9.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.

Authors:  A Schömig; F J Neumann; A Kastrati; H Schühlen; R Blasini; M Hadamitzky; H Walter; E M Zitzmann-Roth; G Richardt; E Alt; C Schmitt; K Ulm
Journal:  N Engl J Med       Date:  1996-04-25       Impact factor: 91.245

Review 10.  Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events. A critical analysis.

Authors:  R Stalnikowicz-Darvasi
Journal:  J Clin Gastroenterol       Date:  1995-07       Impact factor: 3.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.